CRL
Charles River Laboratories International, Inc. · Healthcare · Medical - Diagnostics & Research
动量输入（同类管理人）：
持有人广度 +11.1% ·
股份流向 +11.8% ·
净新建仓位 +10.0%
· 公式
广泛增持：持股数量上升，持有人数量增加
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q2 2025
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 138 | -1 | 45.11M | $10.22B | +6 | −8 |
| Q1 2026 | 143 | -7 | 45.52M | $7.86B | +6 | −14 |
| Q4 2025 | 150 | +3 | 43.69M | $8.72B | +4 | n/a |
| Q3 2025 | 22 | 0 | 23.18M | $3.62B | +1 | −2 |
| Q2 2025 | 20 | +2 | 21.36M | $3.24B | +4 | −2 |
| Q1 2025 | 15 | 0 | 9.57M | $1.44B | +1 | −1 |
| Q4 2024 | 15 | +1 | 9.65M | $1.78B | +1 | n/a |
| Q3 2024 | 13 | -1 | 6.67M | $1.31B | n/a | −1 |
| Q2 2024 | 14 | n/a | 3.92M | $810.09M | n/a | n/a |
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (被动) | 5.81M | n/a | $881.82M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 2 | Wellington Management ✦ | 3.77M | -12.1% | $571.69M | 0.1% | ▼ Trim | 5 | SEC ↗ ×8 |
| 3 | BlackRock ✦ (被动) | 3.66M | n/a | $554.74M | 0.0% | n/c | 1 | SEC ↗ ×18 |
| 4 | State Street Global Advisors ✦ (被动) | 1.86M | -2.3% | $282.03M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | Geode Capital Management ✦ (被动) | 1.23M | -2.5% | $186.60M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 6 | Harris Associates (Oakmark) ✦ | 1.16M | 新增 | $176.45M | 0.3% | New | 1 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 607.02K | 新增 | $92.10M | 0.1% | New | 1 | SEC ↗ ×2 |
| 8 | Arrowstreet Capital ✦ | 578.61K | +63.6% | $87.79M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 564.59K | +100.2% | $85.67M | 0.1% | ▲ Add | 5 | SEC ↗ ×2 |
| 10 | Millennium Management ✦ | 507.32K | +580.9% | $76.98M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 11 | Norges Bank ✦ (被动) | 507.16K | +15.8% | $76.95M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 12 | PRIMECAP Management ✦ | 270.60K | -0.8% | $41.06M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 13 | Gotham Asset Management ✦ | 269.16K | +73.9% | $40.84M | 0.2% | ▲ Add | 5 | SEC ↗ |
| 14 | Point72 Asset Management ✦ | 236.41K | 新增 | $35.87M | 0.1% | New | 1 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 93.67K | -42.6% | $14.21M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 16 | Fidelity (FMR) ✦ | 78.32K | n/a | $11.88M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 17 | T. Rowe Price ✦ | 74.47K | -2.0% | $11.30M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 18 | Adage Capital Partners ✦ | 45.00K | 新增 | $6.83M | 0.0% | New | 1 | SEC ↗ |
| 19 | AQR Capital Management ✦ | 26.76K | +329.1% | $4.02M | 0.0% | ▲ Add | 5 | SEC ↗ ×5 |
| 20 | Marshall Wace ✦ | 14.07K | -62.9% | $2.14M | 0.0% | ▼ Trim | 5 | SEC ↗ ×3 |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| Harris Associates (Oakmark) | $176.45M | 0.3% |
| D. E. Shaw & Co. | $92.10M | 0.1% |
| Point72 Asset Management | $35.87M | 0.1% |
| Adage Capital Partners | $6.83M | 0.0% |
已清仓
| Fisher Asset Management | $38.42M | 曾为 0.0% |
| Baillie Gifford | $7,375 | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 555 持有人, 56.84M 股份, $9.32B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
Officer · EVP & Chief Financial… · 10 股 @ 297.43 · $2,974
公开市场卖出 (S)
Officer · 981 股 · $302,580
Director · 33.56K 股 · $10.07M
Officer · 2.04K 股 · $599,711
Director · 573 股 · $163,443
Officer, Director · 6.50K 股 · $1.82M
Officer · 3.71K 股 · $1.04M
Director · 28.73K 股 · $7.90M
Officer · 620 股 · $163,643
Officer · 482 股 · $127,812
Officer · 404 股 · $104,446
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论